Review
Copyright copy;2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 7, 2010; 16(33): 4130-4134
Published online Sep 7, 2010. doi: 10.3748/wjg.v16.i33.4130
Epstein-Barr virus: Silent companion or causative agent of chronic liver disease?
Mihaela Petrova, Victor Kamburov
Mihaela Petrova, Clinic of Gastroenterology, Ministry of Interior, Sofia 1606, Bulgaria
Victor Kamburov, Gastroenterology Division, First Multiprofile Hospital for Active Treatment, Sofia 1142, Bulgaria
Author contributions: Petrova M wrote the first draft of the manuscript; Kamburov V contributed to the subsequent drafts and equally to the general idea and structure of the manuscript.
Correspondence to: Dr. Mihaela Petrova, PhD, Clinic of Gastroenterology, Ministry of Interior, MI, 79, “Skobelev” Blvd, Sofia 1606, Bulgaria. mpetrova@gmail.com
Telephone: +359-2-9821356 Fax: +359-2-8964880
Received: February 16, 2010
Revised: March 22, 2010
Accepted: March 29, 2010
Published online: September 7, 2010
Abstract

The Epstein-Barr virus (EBV) has an important and multifaceted role in liver pathology. As a member of the herpes virus family, EBV establishes a persistent infection in more than 90% of adults. Besides acute hepatitis during primary infection, many clinical syndromes of interest for the hepatologist are associated with EBV infection. The role of EBV in the evolution of chronic hepatitis from hepatotropic viruses is considered. Chronic EBV-associated hepatitis is suspected in immunocompetent adults with compatible serology, suggestive histology and detection of the viral genome in the liver and/or increase of specific circulating cytotoxic T-lymphocytes. EBV is the main cause of post-transplant lymphoproliferative disorders which occur in up to 30% of cases. EBV-driven lymphoproliferative diseases are also recognized in non-immunocompromised patients and liver is involved in up to a third of the cases. Directly implicated in the pathogenesis of different tumors, EBV has a disputable role in hepatocellular carcinoma carcinogenesis. Further research is required in order to establish or reject the role of EBV in human liver cancer. This paper attempts to discuss the range of EBV-associated chronic liver diseases in immunocompetent patients, from mild, self-limiting mononuclear hepatitis to liver cancer.

Keywords: Epstein-Barr virus, Chronic hepatitis, Liver disease, Chronic active Epstein-Barr virus, Post-transplant lymphoproliferative disorder, Infectious mononucleosis